Clinical Trial News

The phase 2 SHIMMER study showed CT1812, an investigational therapy for dementia with Lewy bodies (DLB), met its primary endpoint of safety and tolerability, with improvements in behavioral, functional, cognitive, and movement measures. CT1812 demonstrated a slowing of decline across cognitive measures and a reduction in caregiver distress. Detailed data will be presented at the 2025 International Lewy Body Dementia Conference.

Novo Nordisk's stock dropped over 20% due to disappointing results from a new drug study, affecting Ypsomed's share price. The study showed CagriSema led to 22.7% weight loss, below the expected 25%, despite Novo Nordisk's optimism.

The FDA approved vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis in patients 6+ with at least 1 F508del mutation or a responsive mutation. Alyftrek, a once-daily CFTR modulator, met primary and secondary endpoints in phase 3 trials, showing non-inferiority to Trikafta in ppFEV1 and superiority in reducing sweat chloride levels.

The FDA approved Zepbound, the first prescription drug for obstructive sleep apnea, for people with obesity and moderate to severe sleep apnea. Studies showed improvement in symptoms with Zepbound compared to a placebo. The drug's compound, tirzepatide, also aids weight loss and is used in diabetes treatment. The approval may increase demand for obesity medications and influence insurance coverage.

FDA approves Eli Lilly's Zepbound for treating moderate to severe obstructive sleep apnea in obese patients, to be used with a reduced-calorie diet and increased physical activity. Clinical trials showed improved sleep apnea symptoms, and the drug's active ingredient, tirzepatide, is also effective for weight reduction.

FDA approves Eli Lilly's Zepbound, a GLP-1 weight-loss drug, for treating moderate to severe obstructive sleep apnea in adults with obesity, marking the first drug treatment option for certain patients with OSA. Zepbound, also known as tirzepatide, significantly improves OSA and aids in long-term weight loss, with nearly half of clinical trial patients no longer experiencing OSA symptoms.

The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. The drug, used with a reduced-calorie diet and exercise, helps reduce OSA symptoms by aiding weight loss, as shown in 52-week studies. This approval reflects growing interest in weight loss drugs for conditions beyond obesity and diabetes.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including breathing pauses, compared to a placebo. The approval marks a significant advancement for OSA patients.

Jefferies analyst Peter Welford anticipates Novo Nordisk shares to drop at least 10%-15% due to disappointing Phase III CagriSema obesity data, showing 20.4% weight loss and potential tolerability issues. The firm maintains an Underperform rating with an $81.50 price target.